share_log

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga Real-time News ·  Dec 31, 2022 05:34

Gainers

  • Invacare (NYSE:IVC) stock rose 14.3% to $0.48 during Friday's after-market session. The market value of their outstanding shares is at $18.1 million.
  • Benitec Biopharma (NASDAQ:BNTC) stock increased by 11.7% to $0.19. The market value of their outstanding shares is at $5.3 million.
  • AlerisLife (NASDAQ:ALR) stock moved upwards by 9.09% to $0.6. The company's market cap stands at $19.5 million.
  • Renalytix (NASDAQ:RNLX) shares rose 8.55% to $2.03. The company's market cap stands at $76.0 million.
  • electroCore (NASDAQ:ECOR) shares increased by 8.52% to $0.28. The market value of their outstanding shares is at $19.8 million.
  • Statera BioPharma (NASDAQ:STAB) stock increased by 8.37% to $0.09. The company's market cap stands at $4.8 million.

Losers

  • Salarius Pharmaceuticals (NASDAQ:SLRX) shares declined by 13.7% to $1.32 during Friday's after-market session. The company's market cap stands at $3.0 million.
  • GreenLight Biosciences (NASDAQ:GRNA) stock declined by 10.17% to $1.06. The company's market cap stands at $160.6 million.
  • Intelligent Bio Solutions (NASDAQ:INBS) stock decreased by 8.91% to $0.18. The market value of their outstanding shares is at $3.3 million.
  • Baudax Bio (NASDAQ:BXRX) stock declined by 8.5% to $2.91. Trading volume for this security closed at 518.1K, accounting for 46.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.6 million.
  • Finch Therapeutics Group (NASDAQ:FNCH) shares decreased by 8.32% to $0.44. The market value of their outstanding shares is at $21.0 million.
  • Adaptimmune Therapeutics (NASDAQ:ADAP) stock declined by 7.54% to $1.35. The company's market cap stands at $221.1 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment